$0.69
7.14% today
Nasdaq, Apr 04, 08:25 pm CET
ISIN
US6963891055
Symbol
PALI
Sector
Industry

Palisade Bio Inc Stock price

$0.64
-0.18 22.18% 1M
-2.92 81.91% 6M
-1.01 60.97% YTD
-5.19 88.96% 1Y
-779.36 99.92% 3Y
-3,149.36 99.98% 5Y
-2,281,499.36 100.00% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.02 3.54%
ISIN
US6963891055
Symbol
PALI
Sector
Industry

Key metrics

Market capitalization $2.83m
Enterprise Value $-6.82m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.56
P/B ratio (TTM) P/B ratio 0.10
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-14.86m
Free Cash Flow (TTM) Free Cash Flow $-12.19m
Cash position $9.82m
EPS (TTM) EPS $-13.03
P/E forward negative
Short interest 10.58%
Show more

Is Palisade Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Palisade Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Palisade Bio Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Palisade Bio Inc forecast:

Buy
100%

Financial data from Palisade Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.79 5.79
5% 5%
-
- Research and Development Expense 9.06 9.06
31% 31%
-
-15 -15
16% 16%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
16% 16%
-
Net Profit -14 -14
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Palisade Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Palisade Bio Inc Stock News

Neutral
GlobeNewsWire
21 days ago
Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108
Neutral
GlobeNewsWire
23 days ago
PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top 10% of all AGA Abstracts Selected for Poster Presentation at DDW
Neutral
GlobeNewsWire
about one month ago
Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC)
More Palisade Bio Inc News

Company Profile

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company is headquartered in Carlsbad, CA.

Head office United States
CEO J. Finley
Employees 8
Founded 2011
Website www.palisadebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today